Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASP-MS: Subcutaneous Cladribine for Non-relapsing SPMS
NCT05961644Phase 3Recruiting
- Sponsor
- Institute of Psychiatry and Neurology
- Start
- Oct 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Cladribine with Placebo (2 arms). Primary endpoint: Percentage brain volume change at 122 weeks. Started Oct 2022; status: recruiting.
02
Drugs
cladribine
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT05961644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961644.